RISPERIDONE        SUPPORTING DATA 
Supporting data
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Risperidone monotherapy for acute mania (1)
Authors: Vieta, et al.
Title: Risperidone in the treatment of manic or mixed episodes of bipolar disorder.
Reference: Poster presented at the 41st ACNP annual meeting, December 2002.
Purpose: To determine the efficacy of risperidone monotherapy in the acute treatment of patients with manic or mixed episodes.
Study design: Randomized, double-blinded, placebo-controlled, 3-week, multicenter trial conducted in India.
Follow up: none specified.
Patients: 290 bipolar I inpatients (146 risperidone, 144 placebo) with a manic or mixed episode (YMRS >20).
Treatment: Risperidone flexible dose (1–6 mg/day) or placebo monotherapy.
Results: Risperidone produced significantly greater improvements in YMRS scores compared with placebo from week 1 onwards. At the endpoint, response rates (>50% reduction in YMRS) were 73% for risperidone and 36% for placebo (p < 0.001). Symtoms of EPS were reported in 35% of risperidone-treated patients versus 6% of placebo-treated patients.
extra-pyramidal symptoms
Young Mania Rating Scale
Young Mania Rating Scale
Young Mania Rating Scale
American College of Neuropsychopharmacology
American College of Neuropsychopharmacology
American College of Neuropsychopharmacology
American College of Neuropsychopharmacology
American College of Neuropsychopharmacology


 
  
home help sitemap acronyms help sitemap home